Ruili Sun

Dr. Ruili Sun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Virology Journal
Verified
Journal Article
Open access
PDF file
XWXiangpeng Wang
Xiangpeng Wang
YSYuan Song
Yuan Song
XWXiaofei Wei
Xiaofei Wei
GWGuanyu Wang
Guanyu Wang
RSRuili Sun
Ruili Sun
LZLijun Zhao
Lijun Zhao
Background: Human papillomavirus (HPV) infection can cause cervical and other cancers, including vulva, vagina, penis, anus, or oropharynx. However, in China's northern Henan Province, data on the prevalence and genotype distribution of HPV among women attending gynecology clinics is limited. This study aimed to investigate the current prevalence and genotype distribution of HPV among women attending gynecology clinics in northern Henan Province. Methods: This study included 15,616 women aged 16–81 years old who visited the Xinxiang central hospital's gynecology department between January 2018 and December 2019. HPV DNA was detected by a conventional PCR method followed by HPV type-specific hybridization, which was designed to detect 17 high-risk HPV (HR-HPV) genotypes and 20 low-risk HPV (LR-HPV) genotypes. HPV prevalence and corresponding 95% confidence intervals (95% CI) were calculated using SPSS 18.0. Results: The overall HPV prevalence was 19.7% among women in northern Henan Province. Single, double, and multiple HPV infections accounted for 13.7%, 4.3%, and 1.8% of the total cases. Most infections were caused by HR-HPV (71.8%), and single genotype HPV infection (13.7%) was the most common pattern. The most common HR-HPV genotype was HPV16 (4.3%), followed by HPV52 (3.5%) and HPV58 (2.0%). The most common LR-HPV genotype was HPV6 (1.4%), followed by HPV61 (1.1%) and HPV81 (1.1%). Conclusions: HPV infection is high among women attending gynecology clinics in northern Henan Province. The highest prevalence was found in women less than 20 years old. In northern Henan Province, the 9-valent HPV vaccine is strongly recommended for regular immunization.

8 February 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
LZLijun Zhao
Lijun Zhao
HQHaonan Qi
Haonan Qi
WLWeiting Liu
Weiting Liu
HLHuiying Lv
Huiying Lv
PLPeixian Li
Peixian Li
XWXiangpeng Wang
Xiangpeng Wang
Pyruvate dehydrogenase B (PDHB) is an important component of the pyruvate dehydrogenase complex and is implicated in altering tumor metabolism and promoting malignancy. However, the specific impact of PDHB on hepatocellular carcinoma (HCC) metabolic reprogramming and its role in tumor progression remain to be elucidated. In our investigation, we have discerned a pronounced elevation in PDHB expression within HCC, intricately linked to delayed tumor staging, heightened tumor grading, and diminished prognostic outcomes. PDHB overexpression drives tumor growth and metastasis in vitro and in vivo. Mechanistically, PDHB mediates metabolic reprogramming by binding to the promoter regions of SLC2A1, GPI, and PKM2, promoting glycolysis-related gene transcription, contributes to HCC sorafenib resistance. In addition, Isoacteoside is a targeted inhibitor of PDHB and exert antitumor effects on HCC. In the mouse xenograft model, the combination of isoacteoside and sorafenib shows significantly better effects than sorafenib alone. In summary, our study validates PDHB as an oncogenic drug resistance-related gene capable of predicting HCC tumor progression. PDHB and Isoacteoside could be potential avenues for targeted and combination therapies in liver cancer.

1 September 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HLHuiying Lv
Huiying Lv
HGHaofei Gong
Haofei Gong
RZRan Zhao
Ran Zhao
XGXuan Gao
Xuan Gao
WLWenyue Liu
Wenyue Liu
RSRuili Sun
Ruili Sun
Metformin, a cornerstone therapy for type 2 diabetes, has recently garnered attention for its multifaceted antitumor potential in cancer prevention and treatment. Emerging preclinical studies reveal that metformin suppresses tumor growth and metastasis through integrated mechanisms beyond singular metabolic pathways, while enhancing sensitivity to immunotherapy. Clinical evidence preliminarily supports its survival benefits and risk reduction in breast, colorectal, and hepatocellular carcinomas, particularly when combined with conventional or novel anticancer agents, demonstrating synergistic efficacy. Epidemiological and real-world data further highlight its preventive value in high-risk populations. Despite heterogeneity in therapeutic responses across cancer types and individuals, as well as unresolved challenges in long-term safety and acquired resistance, innovative drug delivery systems and precision oncology approaches are expanding its therapeutic boundaries. Bridging mechanistic insights with clinical translation, metformin is poised to emerge as a pivotal agent in metabolic-immunological synergy, offering novel paradigms for personalized cancer interception and therapy. This review systematically deciphers metformin's pleiotropic mechanisms in cancer metabolism and anti-tumor immunity while critically evaluating its translational prospects, thereby illuminating new avenues for combinatorial metabolic-immunotherapeutic strategies.